Comparative Pharmacology
Head-to-head clinical analysis: TRIVARIS versus VASCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIVARIS versus VASCOR.
TRIVARIS vs VASCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
VASCOR (bepridil) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, reducing contractility and oxygen demand. It also has class I and IV antiarrhythmic properties.
TRIVARIS 10 mg orally once daily, with or without food.
Bepridil hydrochloride (Vascor) is typically dosed as 200 mg to 400 mg orally once daily.
None Documented
None Documented
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Terminal elimination half-life: 6-8 hours (normal renal/hepatic function). May be prolonged in hepatic impairment; unchanged in renal impairment.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Primarily hepatic metabolism; ~70% excreted in feces as metabolites, ~30% in urine (largely as metabolites). <2% excreted unchanged in urine.
Category C
Category C
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination
Calcium Channel Blocker